Table 1.
Abbreviations
Abbrev. | Definition | Abbrev. | Definition |
---|---|---|---|
ABA | Applied behavioral analysis | IQ | Intelligence (Quotient) |
ACTH | Adrenocorticotropic hormone, corticotropin | LGS | Lennox–Gastaut syndrome |
AD | Antidepressant | LKS | Landau–Kleffner syndrome |
AD | MAOI | Monoamino oxidase inhibitor | |
ADHD | Attention deficit/hyperactivity syndrome | MPEP | 2‑methyl-6- (phenylethynyl)pyridine |
BD | Bipolar disorder | MT1 | Melatonin 1 (receptor) |
ASD | Autism spectrum disorder | NDRI | Norepinephrine-dopamine reuptake inhibitor |
BPD | Borderline personality disorder | NMDA | N‑methyl-D-aspartate |
CBT | Cognitive behavioral therapy | OCD | Obsessive compulsive disorder |
CSWS | Continuous spike waves during slow-wave sleep | ODD/CD | Oppositional defiant disorder/conduct disorder |
DSM‑5 | Diagnostic and Statistic Manual for Mental Disorders, 5th edition | PE | Partial epilepsy |
DRESS | Drug rash with eosinophilia and systemic symptoms | PECS | Picture exchange communication system |
EF | Executive functions (functioning) | REM sleep | Rapid eye movement sleep |
ESES | Electrical status epilepticus during slow-wave sleep | RLS | Restless legs syndrome |
FDA | Food and Drug Administration | SGA | Second generation antipsychotic |
FGA | First generation antipsychotic | SSRI | Selective serotonin reuptake inhibitor |
FXS | Fragile X syndrome | SNRI | Selective serotonin and norepinephrine reuptake inhibitor |
GABA | Gamma-amino-butyric acid | SE | Side effects |
GAD | Generalized anxiety disorder | Half life | |
CBT | Cognitive behavioral therapy | TCA | Tricyclic antidepressant |
ICD | International Classification of Diseases | TCM | Traditional Chinese medicine |
ID | Intellectual disability | TEACCH | Treatment and education of autistic and related communication handicapped children |
IGF‑1 | Insulin-like growth factor – 1 | VPS | Valproic acid |